Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) Enterprise Value (2016 - 2025)

Standard Biotools (LAB) has disclosed Enterprise Value for 16 consecutive years, with -$65.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Enterprise Value rose 82.19% to -$65.5 million in Q3 2025 year-over-year; TTM through Mar 2025 was -$258.1 million, a 44.33% increase, with the full-year FY2024 number at -$292.9 million, down 153.15% from a year prior.
  • Enterprise Value was -$65.5 million for Q3 2025 at Standard Biotools, up from -$78.5 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$29.5 million in Q4 2021 to a low of -$463.6 million in Q1 2024.
  • A 5-year average of -$168.7 million and a median of -$143.1 million in 2023 define the central range for Enterprise Value.
  • Peak YoY movement for Enterprise Value: tumbled 565.73% in 2022, then soared 82.19% in 2025.
  • Standard Biotools' Enterprise Value stood at -$29.5 million in 2021, then tumbled by 466.05% to -$166.8 million in 2022, then skyrocketed by 30.64% to -$115.7 million in 2023, then tumbled by 153.15% to -$292.9 million in 2024, then soared by 77.64% to -$65.5 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Enterprise Value are -$65.5 million (Q3 2025), -$78.5 million (Q2 2025), and -$258.1 million (Q1 2025).